HTA Council Recommendation on Bivalent COVID-19 Vaccines as Booster

HTA Council Recommendation on Bivalent COVID-19 Vaccines as booster Date of OIC-SOH Approval: 25 April 2023 This assessment followed the HTA Council evaluation framework to evaluate COVID-19 vaccines using the following criteria: (1) responsiveness to magnitude and severity; (2) clinical efficacy and safety; (3) affordability, viability and feasibility; (4) household financial impact; (5) social impact; and continue reading : HTA Council Recommendation on Bivalent COVID-19 Vaccines as Booster

[Announcement] HTA Council Releases Its Preliminary Recommendation on the Financing of DOACs for Nonvalvular Atrial Fibrillation

The Health Technology Assessment (HTA) Council releases its preliminary recommendation on the government financing of apixaban, dabigatran, and rivaroxaban for the prevention of myocardial infarction, cerebrovascular diseases and other cardiovascular events among patients with nonvalvular atrial fibrillation (NVAF) and subgroups of NVAF patients through its inclusion in the Philippine National Formulary.Appeals will be accepted from continue reading : [Announcement] HTA Council Releases Its Preliminary Recommendation on the Financing of DOACs for Nonvalvular Atrial Fibrillation